Sign In
Buy SIBN
$15.84
+0.630 (+4.14%)
At Close: Jun 18, 2026
SI-BONE, Inc. (SIBN) Q3 2023 Earnings Call Transcript
09:22pm, Monday, 06'th Nov 2023
SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of IR Laura Francis - CEO Anshul Maheshwari - CFO Conferenc
SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance
04:09pm, Monday, 06'th Nov 2023
Annual guidance increased to $136 million - $137 million, implying annual growth of 28%-29% Annual guidance increased to $136 million - $137 million, implying annual growth of 28%-29%
SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023
04:09pm, Wednesday, 01'st Nov 2023
SANTA CLARA, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced
SI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023
04:09pm, Monday, 16'th Oct 2023
SANTA CLARA, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced
Si-Bone (SIBN) Upgraded to Buy: Here's Why
01:32pm, Monday, 09'th Oct 2023
Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Has SiBone (SIBN) Outpaced Other Medical Stocks This Year?
11:17am, Friday, 08'th Sep 2023
Here is how Si-Bone (SIBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
SI-BONE: Another Record Quarter, Reinvesting For Future Growth, Reiterate Buy
04:28pm, Thursday, 31'st Aug 2023
SI-BONE, Inc. presents compelling long-term value with robust growth in unit economics, high gross profits, and attractive valuation upside. Q2 FY'23 showed record-breaking sales of $33.3 million, wit
SI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023
04:09pm, Tuesday, 29'th Aug 2023
SANTA CLARA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced
SI-BONE, Inc. (SIBN) Q2 2023 Earnings Call Transcript
09:40pm, Monday, 07'th Aug 2023
SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Saqib Iqbal - Senior Director, FP&A and Investor Relations Laura Francis - Chief Executive
SI-BONE to Present at Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023
04:09pm, Wednesday, 19'th Jul 2023
SANTA CLARA, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced
SI-BONE To Report Second Quarter 2023 Financial Results on August 7, 2023
05:07am, Saturday, 15'th Jul 2023
SANTA CLARA, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced
Best Momentum Stocks to Buy for July 6th
11:35am, Thursday, 06'th Jul 2023
NCR, GBX and SIBN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 6, 2023.
New Strong Buy Stocks for July 6th
08:35am, Thursday, 06'th Jul 2023
GBX, GFF, AVDX, NCR and SIBN have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2023.
SI-BONE: Rating Higher On Fundamental, Economic Grounds
12:14pm, Thursday, 15'th Jun 2023
SI-BONE is pushing higher in revenues and gross profit, clipping another strong quarter. It pulled in 80% gross margin and expects this on a revised FY'23 outlook. Additional fundamental catalysts are
SI-BONE To Present at Jefferies 2023 Healthcare Conference on June 7, 2023
04:09pm, Wednesday, 24'th May 2023
SANTA CLARA, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced
